- Published at
- by seekingalpha.com
neutral
neutral
GenSight Biologics S.A. reports FY results (OTCMKTS:GSGTF)
Discover GenSight Biologics' FY financials: GAAP EPS of -€0.15 & €2.6M operating income.
News for GenSight Biologics S.A. (GSGTF)
- Published at
- by investing.com
positivepositiveGenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ ® Gene Therapy By Investing.com
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ ® Gene Therapy- Published at
- by investing.com
positivepositiveGenSight Biologics Announces Submission of LUMEVOQ ® Dossier to ANSM to Prepare for Restart of Early Access Program in France By Investing.com
GenSight Biologics Announces Submission of LUMEVOQ ® Dossier to ANSM to Prepare for Restart of Early Access Program in France- Published at
- by investing.com
positivepositiveGenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ ® By Investing.com
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ ®- Published at
- by seekingalpha.com
neutralneutralGenSight Biologics S.A. reports 1H results (OTCMKTS:GSGTF)
GenSight Biologics S.A. reports lower revenues in the first half of 2024, with EPS at -€0.26.- Published at
- by investing.com
positivepositiveGenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update By Investing.com
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update- Published at
- by investing.com
positivepositiveGenSight Biologics Launches Newsletter for Retail Investors By Investing.com
GenSight Biologics Launches Newsletter for Retail Investors- Published at
- by investing.com
positivepositiveGenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates By Investing.com
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates- Published at
- by investing.com
positivepositiveGenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings By Investing.com
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings- Published at
- by investing.com
positivepositiveGenSight Biologics Appoints William Monteith to its Board of Directors By Investing.com
GenSight Biologics Appoints William Monteith to its Board of Directors- Published at
- by marketscreener.com
positivepositiveGenSight Biologics S A : 2024 AGM Result
Press Release Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting ...- Published at
- by seekingalpha.com
mixedmixedVoyager Therapeutics: A Shot At Making Gene Therapy Deliver Easier (NASDAQ:VYGR)
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why the best days are ahead for VYGR stock.VYGR.MXVYGRSRPTSLDBSIGHT.PARGNXPRVLPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFEPASGNVSN.MXNVSEFNVSD.BANVSNOVN.SWN1VS34.SAIONS.MXIONSIDP.DEGSGTFBIIBD.BABIIBCL.SNBIIB.SNBIIB.MXBIIB.BABIIBABBV34.SAABBV.MXABBV.BAABBV4AB.DE0RIM.L0L35.L0K9E.L0JDI.LZEG.DEUQ1.DETSHASGMOQURENBIXLLY.MXLLY.DELLY.BALLYLILY34.SAGBY.DEFOLD.MXFOLDFDMTDUL.DEBMRNAZNN.MXAZNCFAZN.LAZNALNYADVMABEOA1LN34.SA0R1D.L0Q1G.L0K6R.L0HNC.L0HF9.L0HD2.L0HA3.L0H7R.L0EE0.L0A4J.L